DUL:F:F-Alnylam Pharmaceuticals Inc (EUR)

COMMON STOCK | Biotechnology |

Last Closing

USD 245.3

Change

+4.20 (+1.74)%

Market Cap

USD 30.08B

Volume

10.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1. In addition, the company develops patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; Belcesiran for the treatment of alpha-1 liver disease; Elebsiran to treat chronic HBV infection; Zilebesiran to treat hypertension; ALN-APP to treat Alzheimer's disease and cerebral amyloid angiopathy; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Roche to develop pharmaceutical products containing zilebesiran. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
NOVA:F Novo Nordisk A/S

-0.50 (-0.42%)

USD 547.87B
NOV:F Novo Nordisk A/S

-1.44 (-1.20%)

USD 547.87B
RGO:F Regeneron Pharmaceuticals Inc

-1.50 (-0.15%)

USD 114.77B
CSJ:F CSL Limited

-1.18 (-0.66%)

USD 88.37B
CSJA:F CSL LTD SPON.ADR 2

-0.50 (-0.56%)

USD 87.08B
UNC0:F UCB S.A. UNSP.ADR 1/2

-3.00 (-3.68%)

USD 30.35B
1AEA:F argenx SE

-14.00 (-2.93%)

USD 29.03B
1AE:F Argen-X

-14.70 (-3.05%)

USD 28.94B
22UA:F BioNTech SE

-7.60 (-6.75%)

USD 26.15B
0QF:F Moderna Inc

-1.80 (-2.78%)

USD 24.99B

ETFs Containing DUL:F

N/A

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 39.53% 81% B- 90% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 39.53% 81% B- 82% B
Trailing 12 Months  
Capital Gain 50.31% 82% B 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 50.31% 81% B- 81% B-
Trailing 5 Years  
Capital Gain 223.66% 86% B+ 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 223.66% 85% B 85% B
Average Annual (5 Year Horizon)  
Capital Gain 15.23% 80% B- 79% B-
Dividend Return 15.23% 80% B- 72% C
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 27.53% 67% D+ 47% F
Risk Adjusted Return 55.34% 90% A- 73% C
Market Capitalization 30.08B 99% N/A 94% A

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.